1996
DOI: 10.1007/978-94-011-3990-8_9
|View full text |Cite
|
Sign up to set email alerts
|

Regulation of cardiac Ca2+ channels by cGMP and NO

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
9
0

Year Published

1997
1997
2010
2010

Publication Types

Select...
8

Relationship

3
5

Authors

Journals

citations
Cited by 9 publications
(9 citation statements)
references
References 161 publications
0
9
0
Order By: Relevance
“…On the one hand, sildenafil might possess consid-erable affinity for PDEs V and III. On the other hand, an intracellular cGMP-dependent inhibition of PDE III resulting in increased myocardial cAMP (2,12) and consequently in increased cardiac performance might be a potential explanation. The inhibition of AMP breakdown by GMP has already been shown in a platelet cell model by Maurice and Haslam in 1990 (13).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…On the one hand, sildenafil might possess consid-erable affinity for PDEs V and III. On the other hand, an intracellular cGMP-dependent inhibition of PDE III resulting in increased myocardial cAMP (2,12) and consequently in increased cardiac performance might be a potential explanation. The inhibition of AMP breakdown by GMP has already been shown in a platelet cell model by Maurice and Haslam in 1990 (13).…”
Section: Discussionmentioning
confidence: 99%
“…By a complex mechanism, increased intracellular cGMP leads to the hyperpolarization of smooth-muscle membranes and subsequent vascular relaxation. Moreover, cGMP is involved in the regulation of myocardial L-type Ca 2 ϩ channel current (ICa): In guinea pig, frog, and human cardiomyocytes, cGMP can also stimulate ICa via inhibition of cGMP-inhibited cyclic adenosine monophosphate (cAMP) PDE (PDE III) (2), thus augmenting cardiac output. PDE isozyme types I, III, IV, and V are present in the human pulmonary artery (3).…”
mentioning
confidence: 99%
“…The mechanism for the increase in cardiac output is unclear; this could be secondary to a reduction in right ventricular afterload, or to a myocardial effect of an increase in cGMP. cGMP has been previously shown in isolated preparations to inhibit myocardial cyclic-AMP breakdown by PDE-3, and thus could theoretically augment cardiac performance (17).…”
Section: Control Groupmentioning
confidence: 99%
“…NO modulates cardiac contractility and rhythm in part via its ability to control the amplitude of I Ca (for reviews see Fischmeister & Méry, 1996; Kelly et al 1996; Kojda & Kottenberg, 1999; Paulus & Shah, 1999; Shah & MacCarthy, 2000). Classically, this regulation is mediated through the generation of cGMP by NO‐stimulated soluble guanylyl cyclase activity.…”
mentioning
confidence: 99%